Recent Posts

Drug Company Protections Are Latest Stumbling Block for Nafta Rewrite

WASHINGTON — President Trump’s ability to get his revised North American Free Trade Agreement through Congress may hinge on a little-noticed provision governing intellectual property protections for new pharmaceutical products. Congressional Democrats have seized on measures in the United States-Mexico-Canada Agreement that establish protections for drug companies, saying they are …

Read More »
Translate »